This patient population, estimated at 200,000 across the U.S. and Europe, has limited or no approved treatment options ... Phase 3 study of brepocitinib in dermatomyositis and Immunovant's ...
This patient population, estimated at 200,000 across the U.S. and Europe, has limited or no approved treatment options, highlighting the significant ... for the Phase 3 study of brepocitinib in ...
a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical stage molecules. We advance our pipeline by creating ...
It is administered through intravenous route. Kyverna Therapeutics (Kyverna) is a cell therapy company that is into advancing treatment options for addressing the unmet medical needs for inflammatory ...
It is administered through intravenous route. Kyverna Therapeutics (Kyverna) is a cell therapy company that is into advancing treatment options for addressing the unmet medical needs for inflammatory ...
Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback